Literature DB >> 16434898

The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

Fabiola Medeiros1, Michael G Muto, Yonghee Lee, Julia A Elvin, Michael J Callahan, Colleen Feltmate, Judy E Garber, Daniel W Cramer, Christopher P Crum.   

Abstract

A proportion of adenocarcinomas in prophylactic adnexectomies (bilateral salpingo-oophorectomies [BSOs]) from women with BRCA mutations (BRCA positive) occur in the fallopian tube. We analyzed a consecutive series of BSOs from BRCA-positive women following an index case of fimbrial serous carcinoma. To determine if the fimbria is a preferred site of origin, we followed a protocol for Sectioning and Extensively Examining the FIMbria (SEE-FIM). Immunostaining for p53 and Ki-67 was also performed. Thirteen BRCA-positive women (cases) and 13 women undergoing BSOs for other disorders (controls) were studied. Tubal carcinoma was detected in 4 cases at the initial histologic evaluation and in no controls. A fifth carcinoma was discovered following further sectioning of the fimbriae. Three were BRCA2 positive and two BRCA1 positive. Three were in the fimbria, one in both the fimbria and proximal tube, and one involved the ampulla. Four were serous carcinomas, four were confined to the tube, and three were noninvasive (intraepithelial). No ovarian carcinomas were identified. All tumors were Ki-67 positive (>75% of cell nuclei), and excluding one endometrioid carcinoma, p53 positive (>75% cell nuclei); p53 positivity in the absence of elevated Ki-67 did not correlate with morphologic neoplasia. The fimbria was the most common location for early serous carcinoma in this series of BRCA-positive women. Protocols that extensively examine the fimbria (SEE-FIM) will maximize the detection of early tubal epithelial carcinoma in patients at risk for ovarian cancer. Investigative strategies targeting the fimbriated end of the fallopian tube should further define its role in the pathogenesis of familial and sporadic ovarian serous carcinomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434898     DOI: 10.1097/01.pas.0000180854.28831.77

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  231 in total

1.  Sex-determining region Y-box 2 expression predicts poor prognosis in human ovarian carcinoma.

Authors:  Jing Zhang; Doo Young Chang; Imelda Mercado-Uribe; Jinsong Liu
Journal:  Hum Pathol       Date:  2012-03-07       Impact factor: 3.466

Review 2.  It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.

Authors:  Ruth Perets; Ronny Drapkin
Journal:  Cancer Res       Date:  2015-12-15       Impact factor: 12.701

3.  Ovarian surface epitheliectomy in the non-human primate: continued cyclic ovarian function and limited epithelial replacement.

Authors:  Jay W Wright; Tanja Pejovic; Leigh Jurevic; Cecily V Bishop; Theodore Hobbs; Richard L Stouffer
Journal:  Hum Reprod       Date:  2011-03-18       Impact factor: 6.918

4.  Dynamics of the primate ovarian surface epithelium during the ovulatory menstrual cycle.

Authors:  Jay W Wright; Leigh Jurevic; Richard L Stouffer
Journal:  Hum Reprod       Date:  2011-03-18       Impact factor: 6.918

5.  Screening for ovarian cancer: imaging challenges and opportunities for improvement.

Authors:  K B Mathieu; D G Bedi; S L Thrower; A Qayyum; R C Bast
Journal:  Ultrasound Obstet Gynecol       Date:  2018-03       Impact factor: 7.299

6.  Expression of ovarian tumour suppressor OPCML in the female CD-1 mouse reproductive tract.

Authors:  Jean S Fleming; H James McQuillan; Melanie J Millier; Grant C Sellar
Journal:  Reproduction       Date:  2009-01-27       Impact factor: 3.906

7.  Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.

Authors:  Laura L Holman; Sue Friedman; Molly S Daniels; Charlotte C Sun; Karen H Lu
Journal:  Gynecol Oncol       Date:  2014-02-28       Impact factor: 5.482

8.  Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.

Authors:  Goli Samimi; Britton Trabert; Máire A Duggan; Jennifer L Robinson; Kisha I Coa; Elizabeth Waibel; Edna Garcia; Lori M Minasian; Mark E Sherman
Journal:  Gynecol Oncol       Date:  2018-03       Impact factor: 5.482

9.  Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Joanne Kotsopoulos; Jan Lubinski; Jacek Gronwald; Cezary Cybulski; Rochelle Demsky; Susan L Neuhausen; Charmaine Kim-Sing; Nadine Tung; Susan Friedman; Leigha Senter; Jeffrey Weitzel; Beth Karlan; Pal Moller; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2014-12-18       Impact factor: 7.396

Review 10.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.